These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2698 related articles for article (PubMed ID: 7512644)

  • 21. Effects of chronic nitric oxide activation or inhibition on early hepatic fibrosis in rats with bile duct ligation.
    Mayoral P; Criado M; Hidalgo F; Flores O; Arévalo MA; Eleno N; Sánchez-Rodríguez A; López-Novoa JM; Esteller A
    Clin Sci (Lond); 1999 Mar; 96(3):297-305. PubMed ID: 10029566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histochemistry of therapeutically relevant enzymes in human tumours transplanted into severe combined immunodeficient (SCID) mice: nitric oxide synthase-associated diaphorase, beta-D-glucuronidase and non-specific alkaline phosphatase.
    Schumacher U; Adam E; Zangemeister-Wittke U; Gossrau R
    Acta Histochem; 1996 Nov; 98(4):381-7. PubMed ID: 8960302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunological detection of nitric oxide synthase(s) in human tissues using heterologous antibodies suggesting different isoforms.
    Springall DR; Riveros-Moreno V; Buttery L; Suburo A; Bishop AE; Merrett M; Moncada S; Polak JM
    Histochemistry; 1992 Nov; 98(4):259-66. PubMed ID: 1281146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nitric oxide synthase activity in human breast cancer.
    Thomsen LL; Miles DW; Happerfield L; Bobrow LG; Knowles RG; Moncada S
    Br J Cancer; 1995 Jul; 72(1):41-4. PubMed ID: 7541238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological reactivity of neoplastic and non-neoplastic associated neovasculature to vasoconstrictors.
    Andrade SP; Beraldo WT
    Int J Exp Pathol; 1998 Dec; 79(6):425-32. PubMed ID: 10319023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The significance of free blood in liquid and solid tumours.
    Van den Brenk HA; Crowe M; Kelly H; Stone MG
    Br J Exp Pathol; 1977 Apr; 58(2):147-59. PubMed ID: 861165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of tumour cells on angiogenesis and vasoconstrictor responses in sponge implants in mice.
    Andrade SP; Bakhle YS; Hart I; Piper PJ
    Br J Cancer; 1992 Nov; 66(5):821-6. PubMed ID: 1384642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiogenesis. Successful growth of tumours.
    Ross R
    Nature; 1989 May; 339(6219):16-7. PubMed ID: 2469961
    [No Abstract]   [Full Text] [Related]  

  • 29. Expression of inducible nitric oxide synthase in dermal microvasculature in psoriasis.
    Rowe A; Farrell A; Kazmi SH; Bunker CB
    Lancet; 1994 Nov; 344(8933):1371. PubMed ID: 7526100
    [No Abstract]   [Full Text] [Related]  

  • 30. Resistance and susceptibility to tumours. I. Local reactivities of various mice to the implanted Bo4 tumour.
    Dvorák R; Rejthar A; Chlumecký J; Jasková J
    Neoplasma; 1968; 15(6):645-56. PubMed ID: 5704184
    [No Abstract]   [Full Text] [Related]  

  • 31. The influence of tumour temperature on ischemia-induced cell death: potential implications for the evaluation of vascular mediated therapies.
    Chaplin DJ; Horsman MR
    Radiother Oncol; 1994 Jan; 30(1):59-65. PubMed ID: 8153381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer therapeutic potential of combinatorial immuno- and vasomodulatory interventions.
    Hatzikirou H; Alfonso JC; Mühle S; Stern C; Weiss S; Meyer-Hermann M
    J R Soc Interface; 2015 Nov; 12(112):. PubMed ID: 26510827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vascular occlusion and tumour cell death.
    Denekamp J; Hill SA; Hobson B
    Eur J Cancer Clin Oncol; 1983 Feb; 19(2):271-5. PubMed ID: 6681772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The current status of targeting tumour vasculature as a means of cancer therapy: an overview.
    Denekamp J
    Int J Radiat Biol; 1991; 60(1-2):401-8. PubMed ID: 1713939
    [No Abstract]   [Full Text] [Related]  

  • 35. Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial.
    Caraceni A; Gangeri L; Martini C; Belli F; Brunelli C; Baldini M; Mascheroni L; Lenisa L; Cascinelli N
    Cancer; 1998 Aug; 83(3):482-9. PubMed ID: 9690541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA for genetic vaccination and therapy.
    Moelling K
    Cytokines Cell Mol Ther; 1997 Jun; 3(2):127-35. PubMed ID: 9287251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma.
    Schultz MZ; Buzaid AC; Poo WJ
    Melanoma Res; 1997 Apr; 7(2):147-51. PubMed ID: 9167181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and activity of partial retro-inverso analogs of the antimetastatic laminin-derived peptide, YIGSR-NH2.
    Zhao M; Kleinman HK; Mokotoff M
    J Pept Res; 1997 Mar; 49(3):240-53. PubMed ID: 9151257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intermediate steps in cellular iron uptake from transferrin. II. A cytoplasmic pool of iron is released from cultured cells via temperature-dependent mechanical wounding.
    Richardson DR; Dickson L; Baker E
    In Vitro Cell Dev Biol Anim; 1996 Sep; 32(8):486-95. PubMed ID: 8889603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening for melanoma and options for its evaluation [see comment].
    Elwood JM
    J Med Screen; 1994 Jan; 1(1):22-38. PubMed ID: 8790483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 135.